Medical Oncology

Liver and Pancreas Tumors   

Questions discussed in this category



Patients oftentimes have cardiac co-morbidities with requirement for anti-coagulation making TKIs, including Bevacizumab, difficult to dose. Would the...

Would you consider single agent IO such as Nivolumab, given data are not strong (Checkmate 459)?

Upfront surgery vs neoadjuvant therapy? And if neoadjuvant therapy, which regimen? Patient has a good PS.

Quite often we encounter cholestatic hyperbilirubinemia, wherein GI and IR do not believe ERCP with stents or PTC will alleviate jaundice. If the pati...

With extensive use of NGS testing, it is commonplace to identify mutations that have no validated therapeutic intervention, but strong biologic signal...

How do you sequence systemic treatment options for metastatic HCC in Patients with Child's Pugh B Cirrhosis?  When do you incorporate immunother...

In your experience, what approach has been successful to bridge to surgery?

Up to six cycles of treatment were given in the ABC02 trial.  Do you offer other treatments if you don't continue gem/cis beyond 24 weeks?

Given the variable and sometimes indolent disease course of these patients, as well as the absence of a clear overall survival benefit in the PROMID&n...

Is there a "best" way to approach treatment of the viral infection i.e concurrently with therapy, prior to therapy, delayed or post therapy? Does this...

If you do employ this strategy, are there a number of liver lesions (eg <4) or duration of response that guide your decision making?

Would you alter your SBRT dose? How long would you hold the VEGF inhibitor before and after? Does the primary matter (e.g. NSCLC vs. colorectal)?

A number of phase 2 trials support various combinations (e.g. gem/ox, cape/cis, cape/ox, 5-FU based) -- how do you decide either between these regimen...

Would you consider adding trastuzumab to cis/gem in the first line? If not, would you consider adding Her2 directed therapy to FOLFIRI or FOLFOX in th...

Do you continue with FOLFIRI for a period and then switch to olaparib (and if so, when do you make that switch) or do you switch directly after FOLFIR...

Patient characteristics would unarguably be a deciding factor, but outside of these how would you approach the situation?

Arterial events have clear instructions to permanently discontinue on the FDA label.  Especially in HCC without many other treatment options, giv...

What features would make you more likely to recommend radiation therapy with chemotherapy?

The GTX (gemcitabine, docetaxel, capecitabine) regimen is listed as a category 2B recommendation in the NCCN guidelines- when would this be ...

With the current data, I'm struggling to justify addition of radiation for potentially resectable disease.  If in favor of RT, do you recommend s...


Papers discussed in this category


Cancer, 2007-11-15

Cancer, 2015-04-01

JAMA, 2012 Jul 11

JAMA, 2008-03-05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20

International journal of radiation oncology, biology, physics, 2011-09-01

American journal of clinical oncology, 2011-02

International journal of radiation oncology, biology, physics, 2013-12-01

JAMA, 2007 Jan 17

Cancer, 1987 Jun 15

Ann Surg, 2007 Nov

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-03-01

Hepatology (Baltimore, Md.), 2015-06

J. Hepatol., 2016-05-01

Eur. J. Cancer, 2011-09-01

Lancet Oncol., 2015-10-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20

Lancet Oncol., 2019 Mar 25

N. Engl. J. Med.,

Lancet,

Lancet, 2017-03-11

JAMA, 2013 Oct 9

Lancet (London, England), 2018-03-24

J. Clin. Oncol., 2020 Feb 27

Annals of surgery, 2019-04-05

N. Engl. J. Med.,

Sci Rep, 2018 Jun 06

J. Hepatol., 2017 Jan 23

The Journal of pathology, 2019-06

N. Engl. J. Med., 2019 Jun 02

Cancer,

J. Clin. Oncol., 2013 Aug 26

Cancer, 2011-09-01

International journal of radiation oncology, biology, physics, 2015-07-01

Cancer treatment reviews, 2017-02

Strahlenther Onkol, 2019 Feb 08

Radiother Oncol, 2018 Jul 09

Oncologist, 2019 Aug 07

Journal of immunotherapy (Hagerstown, Md. : 1997), 2013-09

J Immunother, 2010 Oct

J. Natl. Cancer Inst., 2017 Jan 28

JAMA Oncol, 2019 Oct 03

J. Hepatol., 2019 Apr 06

Ann. Surg.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-04-01

JAMA oncology, 2019-06-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-04-10

Cancer, 2019-09-15

Clin. Cancer Res., 2015 Oct 23

Int J Cancer, 2018 Apr 15

JAMA Oncol, 2019 Oct 31

Eur J Surg Oncol, 2014 Oct 07

Sci Rep, 2016 May 20

JAMA Netw Open, 2020 Feb 05

Clinical cancer research : an official journal of the American Association for Cancer Research, 2007-06-15

Seminars in oncology, 2003-08

Annals of oncology : official journal of the European Society for Medical Oncology, 2003-07

J. Clin. Oncol., 2020 Jan 24

Lancet Oncol., 2020 Mar 02

Lancet (London, England), 2017-06-24

The Lancet. Oncology, 2018-07

J. Clin. Oncol., 2019 Dec 02

Proceedings of the National Academy of Sciences of the United States of America, 2015-11-03

Oncologist, 2020 Mar 10

Semin Diagn Pathol, 2016 Dec 23